Drug Hunter
JUNE 25, 2023
Maze’s Oral GYS1 Inhibitor, MZE001 Sanofi is paying $150 million plus up to $600 million in milestones for Maze Therapeutics’ glycogen synthase 1 (GYS1) program, including MZE001, which aims to reduce glycogen substrate build-up in Pompe disease.
The Pharma Data
NOVEMBER 15, 2020
” “We are committed to advancing innovative science and transformative medicines for people affected by different immune mediated diseases”, says James Sabry , Global Head, Roche Pharma Partnering. ” About Immune Mediated Diseases. A wide range of human diseases is driven by deregulated immune function.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
DrugBank
JUNE 27, 2024
Opportunities in Drug Repurposing There is great potential for drug repurposing to unlock treatments for rare and neglected diseases, where traditional drug development is too costly. Pharma companies are often rich with valuable chemical libraries and expertise, while academics bring emerging disease biology knowledge.
The ChEMBL-og
DECEMBER 12, 2024
AI-driven Structure-enabled Antiviral Platform (ASAP) (src_id = 71): The AI-driven Structure-enabled Antiviral Platform (ASAP, asapdiscovery.org), funded by National Institute of Allergy and Infectious Diseases is dedicated to the development of novel chemical assets that have antiviral activity against viral families with future pandemic potential.
Sygnature Discovery
APRIL 18, 2023
Sygnature Discovery is pleased to have entered into a research collaboration agreement with the global healthcare group Daewoong Pharmaceutical to accelerate the discovery of a novel small molecule to target autoimmune disease.
DrugBank
OCTOBER 17, 2024
Computational chemistry and molecular modeling techniques can predict potential drug candidates' binding affinity and pharmacokinetic properties, enabling the selection of the most promising compounds for further development.
Practical Cheminformatics
DECEMBER 7, 2023
A recent editorial by Dean Brown in J Med Chem and follow-up posts by Keith Hornberger and Derek Lowe prompted me to think about how we train computational chemists and cheminformaticians for careers in drug discovery. It also brought to mind some unique differences between how computational chemistry is practiced in biotech and pharma.
Expert insights. Personalized for you.
130 
Let's personalize your content